Updated results from phase III FIRST (MM-020/IFM 07-01) trial for Revlimid (lenalidomide) in newly diagnosed multiple myeloma-Celgene
Celgene International S�rl, announced updated results of its pivotal phase III FIRST (MM-020/IFM 07-01) trial, comparing continuous Revlimid (lenalidomide) plus low-dose dexamethasone (continuous Rd) to a fixed duration of 18 cycles of Rd (72 weeks) (Rd18) or 12 cycles of melphalan, prednisone and thalidomide (72 weeks) (MPT) for the treatment of transplant ineligible patients with newly diagnosed multiple myeloma. The results, as part of the Regulatory submissions which led to the Revlimid label expansion in the US and EU in February 2015, were presented during the European Hematology Association annual congress.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins